Biotheus and Hansoh Pharma Expand Partnership for EGFR/cMET Bispecific Antibody-Drug Conjugate Development
Saturday, March 16, 2024
Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd. have jointly announced an extension of their strategic collaboration in the development of biologics for oncology and inflammatory diseases. This collaboration builds upon their partnership since 2022. Under the new agreement, Biotheus will grant Hansoh Pharma a license to use its proprietary anti-EGFR/cMet bispecific antibody, PM1080/HS-20117, for the development of antibody-drug conjugate products (ADC Product).
According to the terms of the agreement, Hansoh Pharma will gain exclusive worldwide rights to utilize PM1080/HS-20117 for the development, production, and commercialization of ADC Products, with the option for sublicensing. In return, Biotheus will receive upfront payments and milestone achievements for ADC Product, as well as royalties based on global net sales from Hansoh Pharma.
PM1080/HS-20117 is currently in phase I clinical trials and is designed as a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, targeting tumor antigens EGFR and cMet to inhibit tumor growth and survival.
Mr. Xiaolin Liu, Co-founder, Chairman, and CEO of Biotheus, expressed appreciation for Hansoh's confidence in PM1080's potential, emphasizing the benefits of bispecific ADCs for tumor treatment. He highlighted the collaboration's goal of developing a novel EGFR/cMet bispecific ADC for cancer patients worldwide.
Ms. Eliza Sun, Executive Director of the Board at Hansoh, also expressed enthusiasm for the expanded partnership, highlighting the combination of Hansoh's ADC Platform technology with Biotheus' bispecific antibody. She expressed confidence in their ability to provide innovative treatment options for cancer patients globally, leveraging their expertise in clinical development, commercialization efforts, and external partnerships.
Source: biotheus.com
